Background-Blood transfusion is associated with acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI). We sought to elucidate in more detail the relation between blood transfusion and AKI and its effects on short-and long-term mortality. 
T ranscatheter aortic valve implantation (TAVI) is increasingly used to treat patients with aortic stenosis, who are considered at high risk for surgical aortic valve replacement. 1 Despite its minimally invasive nature, TAVI is invariably associated with a number of complications that may affect outcome. Some of these complications are clinically manifest during the procedure for which immediate actions are taken, whereas others such as acute kidney injury (AKI) are detected later and may have silent, but harmful, prognostic effects. AKI is reported in 12% to 57% of the patients who undergo TAVI and is associated with a 2-to 6-fold increased risk of death during short-and longterm follow-up. [2] [3] [4] [5] [6] [7] [8] [9] [10] At present, the pathophysiologic mechanisms of AKI after TAVI are unclear. Some studies suggest a direct relation between perioperative blood transfusion and AKI. 5, 6, 10 This may be explained by the fact that in association with the transfusion of red blood cells (RBC) a number of other cellular and molecular substances are administrated that either directly or indirectly (eg, inflammation) induce kidney damage, 11 yet one may question whether the triggers for blood transfusion, such as perioperative blood loss because of bleeding-vascular complications may also play a role. This also holds for the presence of baseline anemia, impaired kidney function, and other procedural factors such as changes in cardiovascular hemodynamics during TAVI. 7, 12 We, therefore, sought to explore in more detail the relation between blood transfusion and AKI after TAVI relative to a number of baseline and procedural variables in a series of 995 patients in addition to the effects of blood transfusion and AKI on mortality.
Methods Patients
Between November 2005 and January 2012, 1050 patients with aortic stenosis underwent TAVI with the Medtronic CoreValve System (Medtronic Inc) or the Edwards SAPIEN Valve (Edwards Life Sciences) in the Erasmus Thoraxcenter, Rotterdam, The Netherlands (n=220); Quebec Heart and Lung Institute, Quebec City, Quebec, Canada (n=216); University Hospital Bonn, Bonn, Germany (n=182); University Hospital Maastricht, Maastricht, The Netherlands (n=145); University Hospital Saint-Luc, Brussels, Belgium (n=122); University Hospital Antwerp, Antwerp, Belgium (n=97); and Angiografia de Occidente, Cali, Colombia (n=68). Patients on chronic hemodialysis (n=35) and those who died within 72 hours precluding creatinine measurements during the first 3 days after TAVI (n=23-including 3 patients on chronic hemodialysis [causes of death are listed in online-only Data Supplement]) were excluded from the study. The final study population consisted, therefore, of 995 patients.
In each institution, patients with symptomatic aortic stenosis were screened at the outpatient clinic during which a structured interview, physical examination, ECG, and blood sampling were performed. Invasive diagnostic workup included a left heart catheterization (performed by the referring institution in most patients) to determine the coronary anatomy and hemodynamic status; echo-(Doppler) cardiography (transthoracic or transesophageal), contrast angiography, or contrast enhanced multisliced CT were performed >2 weeks before TAVI to assess the valvular and vascular anatomy and to define the vascular access strategy (transfemoral, transapical, transsubclavian, transaortic). Treatment eligibility was based on previously described patient-selection criteria, and final acceptance for TAVI was established by Heart Team consensus. 13 In accordance with the institutions policies, every patient gave written informed consent for TAVI and the use of anonymous clinical, procedural and follow-up data for research in accordance with Institutional Review Board approval. This study complies with the Declaration of Helsinki.
Procedure
TAVI was performed under general or local anesthesia using the Medtronic CoreValve System (26, 29, or 31 mm) or Edwards SAPIEN Valve (20, 23 , or 26 mm) via a transfemoral, transapical, transsubclavian, or transaortic approach of which details have been described previously. [14] [15] [16] [17] [18] Details of the prehydration protocol for the various institutions are summarized in online-only Data Supplement.
The amount of contrast and the occurrence of life-threatening arrhythmias (any episode of ventricular tachycardia, ventricular fibrillation, asystole requiring vasopressive drugs, electric defibrillation, or cardiopulmonary resuscitation), any complication leading to severe sustained hypotension, postimplantation balloon dilation, and (Valve Academic Research Consortium-defined) bleeding and vascular complications were recorded during or immediately after TAVI. 19 After the procedure, patients were extubated in the catheterization room or after transfer in the cardiac care unit shortly after the procedure or later if clinically indicated. Antiplatelet therapy after Medtronic CoreValve System and Edwards SAPIEN Valve implantation consisted of clopidogrel 75 mg for 6 months and aspirin 80 to 100 mg indefinitely. Patients on oral anticoagulant therapy before TAVI received periprocedural therapeutic anticoagulation with unfractionated heparin or low-molecular-weight heparin in combination with either clopidogrel or aspirin to cover the time with subtherapeutic INR levels. Oral anticoagulation was resumed shortly after TAVI.
Laboratory Measurements and AKI Definition
Preoperative serum creatinine (SCr) values were used to calculate the baseline SCr clearance using the Cockcroft and Gault equation: SCr clearance (mL/min)=(140−age)×weight (kg)÷72×SCr (mg/dL) (×0.85 for women). 20 Chronic kidney disease (CKD) was defined as a calculated SCr clearance <60 mL/min. 21, 22 Patients with CKD were further classified in tertiles to examine the effect of mild (45.0-60.0 mL/min), moderate (35.0-44.9 mL/min), and severe CKD (<35 mL/min).
AKI was defined according to the Valve Academic Research Consortium recommendations as an absolute (≤72 hours) reduction in kidney function and defined as: (1) Preoperative hemoglobin (Hb) values were used to define baseline anemia according to the American College of Physicians and WHO criteria as a Hb level <13 g/dL in men and <12 g/dL in women. 23 Patients with anemia were classified in tertiles to assess the effects of mild (12.0-12.99 g/dL in men; 11.30-11.99 g/dL in women), moderate (10.80-11.99 g/dL in men; 10.23-11.29 g/dL in women), and severe anemia (<10.80 g/dL in men, <10.23 g/dL in women).
Data on RBC transfusions were recorded by the institution's blood bank laboratory and used to determine the corrected Hb drop ≤24 hours after TAVI according to the modified Landefeld equation. 24, 25 In this equation 1 unit of packed RBCs is considered to represent 1 g/dL of Hb and, therefore, the net Hb drop corresponds to the addition of the number of packed RBC to the baseline-minus-measured nadir Hb. 
Follow-Up
After hospital discharge, mortality data were collected by contacting the civil registries or the referring physician or general practitioner
WHAT IS KNOWN
• Perioperative blood transfusion has been associated with acute kidney injury after transcatheter aortic valve implantation.
WHAT THE STUDY ADDS
• Blood transfusion was the most important factor associated with acute kidney injury whereas potential triggers of transfusion, such as baseline anemia, vascular-bleeding complications, blood loss, or severe hypotension, were not.
• Patients with anemia had less decline in hemoglobin after transcatheter aortic valve implantation but received more transfusions as compared with patients without anemia.
• Acute kidney injury was a predictor of both shortand long-term mortality whereas blood transfusion predicted long-term mortality. 
Statistical Analysis
Details of data completeness and management are summarized in online-only Data Supplement. Categorical variables are presented as frequencies and percentages and were compared with the χ 2 test or Fisher exact test. The normality of distributions was assessed with the Shapiro-Wilk test; comparison of continuous variables was done by using the Student t test or Wilcoxon rank-sum test when appropriate. A stepwise logistic regression analysis including all variables from Tables 1 and 2 exhibiting P<0.10 in the univariable analysis was used to determine the predictive factors of AKI and 30-day mortality. Two interaction terms were tested to evaluate synergistic effects of (1) baseline anemia and Hb drop ≤24 hours and (2) baseline CKD and contrast load. 10 A stepwise Cox regression analysis including all variables from Tables 1 and 2 exhibiting P<0.10 in the Cox univariable analysis was used to determine the predictive factors of long-term mortality in patients who survived the first 30 days after TAVI (landmark analysis). For the purpose of this AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; and IQR, interquartile range. *Chronic kidney disease was defined as a calculated creatinine clearance <60 mL/min; mild 45.0 to 60.0 mL/min, moderate 35.0 to 44.9 mL/min and severe <35 mL/min. †Anemia was defined as Hb <13 g/dL in men and <12 g/dL in women, 23 mild anemia 12.0 to 12.99 g/dL in men and 11.30 to 11.99 g/dL in women, moderate anemia 10.80 to 11.99 g/dL in men and 10.23 to 11.29 g/dL in women, and severe anemia <10.80 g/dL in men and <10.23 g/dL in women.
by guest on June 19, 2017 http://circinterventions.ahajournals.org/ Downloaded from study, RBC transfusion was forced into the multivariable analyses for predictors of AKI, whereas both RBC transfusion and AKI were forced into the multivariable analyses of 30-day and late mortality, irrespective of the P value obtained from the univariable analyses. Variables included in the multivariable model for the prediction of AKI, 30-day mortality, and long-term mortality are listed in onlineonly Data Supplement. Results are reported as adjusted OR or hazard ratio (HR) with a 95% CI. Survival curves for time-to-event variables were constructed on the basis of all available follow-up data in patients who survived the first 30 days after TAVI (landmark analysis) with the use of Kaplan-Meier estimates and were compared with the log-rank test. Patients lost to follow-up (1.6%) were considered at risk until the date of last contact, at which point they were censored. A 2-sided P<0.05 was considered to indicate significance. All statistical analyses were performed with SPSS software (version 17).
Results
The baseline patient characteristics and perioperative details of the total population and of the patients with and without AKI are summarized in Tables 1 and 2 , respectively. AKI occurred in 20.7% (n=206) of the patients of whom 3.1% (n=31) received renal replacement therapy. Details of AKI (stages I-III) and other changes in renal function are depicted in Figure 1 . Patients with AKI had a significantly higher mortality at 30 days and during follow-up ( Table 2) .
Predictors of AKI
By univariable analysis, patients with AKI had a higher prevalence of congestive heart failure (66 versus 56%, P=0.010) and peripheral vascular disease (39 versus 28%, P=0.004) explaining a higher operative risk (Logistic EuroSCORE 22 Table 2 ). Despite the latter, there was no difference in perioperative blood loss (corrected Hb drop) between patients with and without AKI, yet patients with AKI received significantly more blood transfusions within 24 and 72 hours after TAVI. Because baseline anemia might affect the decision to administer blood transfusion, the mean Hb drop and number of blood transfusions for patients with no and with various degrees of baseline anemia was analyzed ( Table 5 ). Kaplan-Meier survival estimates for increasing severity of AKI, baseline anemia, and number of transfusions are shown in Figure 3 .
Discussion
In this multicenter study including 995 patients who underwent TAVI we found that AKI occurred in 21% of the patients and that the number of perioperative blood transfusions was the strongest predictor of AKI but not the clinical indications of transfusion (ie, baseline anemia, perioperative vascularbleeding complications, or blood loss). AKI was a predictor of both short-and long-term mortality, whereas blood transfusion predicted long-term mortality.
The frequency of AKI after TAVI has been reported to vary between 12% and 57% in previous but smaller series of patients using various definitions of AKI. [2] [3] [4] [5] [6] [7] [8] [9] [10] The herein reported point estimate of 21% most likely reflects the incidence of AKI encountered in clinical practice, given the sample size and the multicenter nature of this study. Irrespective of the true value, AKI poses a clinical problem as it is associated with an increased mortality at 30 days and beyond. This has also been shown by others and suggests that the outcome of TAVI may be improved by-among others-implementing all measures to prevent AKI. [5] [6] [7] [8] [9] [10] For that purpose it is essential to understand the pathophysiologic mechanism(s) of AKI after TAVI. Unfortunately, a clinical study such as this one cannot do so, yet the analysis of the association between AKI and patient-and procedure-related variables that are readily available (eg, patient demographics) or subject to change or improvement (eg, execution of procedure) may be helpful.
With respect to execution of the procedure, the findings of this study indicate that AKI and, therefore, outcome may be improved by a more careful use of blood transfusions. As mentioned, the number of blood transfusions was found to be the strongest predictor of AKI with a distinct gradient of risk. The relation between AKI and transfusion is consistent with other reports that studied patients who underwent TAVI or cardiac surgery, 5, 6, 10, 26, 27 yet, such a strong relationship between AKI and the number of transfusions has not been reported. Noteworthy, we also found that the clinical triggers upon which one may decide to administer blood during TAVI were not associated with AKI. If true, this suggests that one should be more restrictive in the use of blood transfusions during TAVI and that the need of unequivocal criteria for the decision of blood transfusion is advocated. This is illustrated by the findings that patients without anemia had a 2.4 times greater Hb drop in comparison with patients with severe baseline anemia. This may be explained by a different patient and procedure planning in addition to differences in the execution of TAVI (ie, control of hemostasis) in patients with different baseline risks. Interventions that reduce perioperative transfusions may protect against AKI, especially in anemic patients. 27 The absence of a relationship between AKI and the indications for transfusion in addition to the fact that we did not find a relationship between AKI and periprocedural complications leading to hypotension supports a direct harmful effect of transfusion on the kidneys. It is known that preserved RBCs suffer structural or functional changes including reduced deformability and increased aggregability, all of which-particularly in older patients with impaired renal function-might induce (further) renal dysfunction. 28 Also the coadministration of proinflammatory molecules may play a role either directly or indirectly by inducing inflammation. 29 This may explain the relation found in this and other studies between postoperative leucocyte count and AKI. 4, 6, 10, 30 At variance with percutaneous coronary intervention (PCI), 31 we found a borderline association between contrast load and AKI in the univariable analysis, yet contrast load was not found to be an independent predictor. The absence of an association cannot be explained by a restrictive use of contrast in the present population considering the mean values and standard deviations (142±97 and 158±96 mL) although this may be an issue of sample size as a result of which a significant statistical difference was not detected. The current findings suggest that unlike PCI, contrast has only a minor effect on the development of AKI in patients who undergo TAVI.
With respect to the patient-related variables and, thus, patient selection, it is unlikely that we will exclude patients with peripheral vascular disease because TAVI was specifically developed for patients who are too high a risk for aortic valve replacement. These patients often have widespread atherosclerosis including the peripheral circulation. It remains to be seen how additional pre-and postoperative care may avoid AKI such as optimal perioperative hydration.
Apart from perioperative blood transfusion and AKI, we found a number of other predictors of early and late mortality after TAVI. In accordance with previous series, we found severe bleeding and postoperative aortic regurgitation to be associated with a 5-fold increased risk of early death, 32 whereas severe baseline anemia, peripheral vascular disease, heart failure, male sex, and atrial fibrillation were independent predictors of late death. 12, 33, 34 These findings confirm the importance of appropriate patient selection to improve outcome after TAVI.
Limitations
This multicenter observational assessment in a large series of patients may estimate the frequency of AKI and its predictors but it cannot elucidate the precise pathophysiologic mechanism(s). This is needed to propose in greater detail improvements in patient and procedure planning and execution in addition to eventual changes in postoperative care. We also acknowledge the formulation of the research question during and after the data collection and the absence of a prespecified case report form. As a result, despite a high degree of completeness (online-only Data Supplement), the timing of the collection of the individual variables may not be consistent, which may affect the precision of the current findings. In addition, there was no uniform protocol of blood transfusion, as a result of which we were are not able to unravel the true triggers of transfusion, thereby precluding specific propositions of improvement.
Conclusions
AKI occurred in 21% of the patients after TAVI. The number of blood transfusions, but not the indication of transfusion, predicted AKI. AKI was a predictor of both short-and long-term mortality, whereas blood transfusion predicted long-term mortality. These findings indicate that the outcome of TAVI may be improved by a more restrictive use of blood transfusions.
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